The rise of systems pharmacology in drug discovery and development

Future Medicinal Chemistry

Volumn 6, Issue 16, 2014, Pages 1731-1734

  Benson, Neil ^a   Van Der Graaf, Piet H ^b  

^a Xenologiq Ltd Unit 43 Canterbury Innovation Centre   (United Kingdom)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B KINASE; NERVE GROWTH FACTOR RECEPTOR; SMALL INTERFERING RNA;

BIOLOGY; BIOTECHNOLOGY; DRUG DEVELOPMENT; HUMAN; INFORMATION TECHNOLOGY; MOLECULAR BIOLOGY; NONHUMAN; OSTEOARTHRITIS; PHARMACOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RECEPTOR OCCUPANCY; REVIEW; SYSTEMS BIOLOGY;

DRUG DISCOVERY; HUMANS; PHARMACOLOGY; SYSTEMS BIOLOGY;

EID: 84911861772     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.66     Document Type: Review

References (22)

1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3(8), 711-715 (2004
2. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9(3), 203-214 (2010
3. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32(1), 40-51 (2014
4. Milligan PA, Brown MJ, Marchant B, et al. Model-based drug development: a rational approach to efficiently accelerate drug development. Clin. Pharmacol. Ther. 93(6), 502-514 (2013
5. van der Graaf PH, Gabrielsson J. Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development. Future Med. Chem. 1(8), 1371-1374 (2009
6. Gabrielsson J, Green AR, van der Graaf PH. Optimising in vivo pharmacology studies-practical PKPD considerations. J. Pharmacol. Toxicol. Methods 61(2), 146-156 (2010
7. Gabrielsson J, Fjellstrom O, Ulander J, Rowley M, van der Graaf PH. Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry. Curr. Top. Med. Chem. 11(4), 404-418 (2011
8. Agoram BM, Martin SW, van der Graaf PH. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics. Drug Discov. Today 12(23-24), 1018-1024 (2007
9. Danhof M, De Lange EC, Della Pasqua OE, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol. Sci. 29(4), 186-191 (2008
10. Gobburu JV, Lesko LJ. Quantitative disease, drug, and trial models. Annu. Rev. Pharmacol. Toxicol. 49, 291-301 (2009
11. Langdon G, Davis JD, Mcfadyen LM, et al. Translational pharmacokinetic-pharmacodynamic modelling; application to cardiovascular safety data for PF-00821385, a novel HIV agent. Br. J. Clin. Pharmacol. 69(4), 336-345 (2010
12. van der Worp HB, Howells DW, Sena ES, et al Can animal models of disease reliably inform human studies? PLoS Med. 7(3), e1000245 (2010
13. Benson N, Cucurull-Sanchez L, Demin O, Smirnov S, van der Graaf P. Reducing systems biology to practice in pharmaceutical company research; selected case studies. Adv. Exp. Med. Biol. 736, 607-615 (2012
14. Berg JM, Rogers ME, Lyster PM. Systems biology and pharmacology. Clin. Pharmacol. Ther. 88(1), 17-19 (2010
15. van der Graaf P. Pharmacometrics and systems pharmacology. CPT Pharmacometrics Syst. Pharmacol. 1, e8 (2012
16. Danhof M, Alvan G, Dahl SG, Kuhlmann J, Paintaud G. Mechanism-based pharmacokinetic-pharmacodynamic modeling-A new classification of biomarkers. Pharmaceut. Res. 22(9), 1432-1437 (2005
17. Cucurull-Sanchez L, Spink KG, Moschos SA. Relevance of systems pharmacology in drug discovery. Drug Discov. Today 17(13-14), 665-670 (2012
18. Ihekwaba AE, Broomhead DS, Grimley RL, Benson N, Kell DB. Sensitivity analysis of parameters controlling oscillatory signalling in the NF-kappaB pathway: the roles of IKK and IkappaBalpha. Systems Biol. 1(1), 93-103 (2004
19. Benson N, Matsuura T, Smirnov S, et al. Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacology. Interface Focus 3(2), 20120071 (2013
20. Benson N, Metelkin E, Demin O, Li GL, Nichols D, van der Graaf PH. A systems pharmacology perspective on the clinical development of fatty acid amide hydrolase inhibitors for pain. CPT Pharmacometrics Syst. Pharmacol. 3, e91 (2014
21. Morgan P, van der Graaf PH, Arrowsmith J, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov. Today 17(9-10), 419-424 (2012
22. Huggins JP, Smart TS, Langman S, Taylor L, Young T. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 153(9), 1837-1846 (2012